Download original image
Fig. 3. Sitagliptin protected HUVECs from injuries caused by high glucose in a dose-dependent manner. Cells were treated with normal glucose, high glucose (33 mM), different concentrations of sitagliptin (0, 0.1, 1, 10, and 100 μM). (A) Cell viability was detected by MTT assay. (B, C) Cell apoptosis was determined by flow cytometry. (D) The productions of IL-1α, IL-6, IL-8, and IL-18 in HG-induced HUVECs were determined by ELISA after treated by different concentrations of sitagliptin. HUVECs, Human umbilical vein endothelial cells; HG, high glucose; S, sitagliptin; IL-1α, interleukin 1 alpha; IL-6, interleukin 6; IL-8, interleukin 8; IL-18, interleukin 18; ELISA, enzyme-linked immunosorbent assay. *p < 0.05 vs. control group, ***p < 0.001 vs. control group. #p < 0.05 vs. HG group. ##p < 0.01 vs. HG group. ###p < 0.001 vs. HG group.
Korean J Physiol Pharmacol 2021;25:425-437
© Korean J Physiol Pharmacol